This work also suggests that DXI is an interesting lead compound with the potential to treat cancers with oncogenic mutations or expression of KRAS and high levels of DX2 (Fig. 5h, i and Supplementary Fig. 12), even if further optimization is needed for better efficacy and safety. Here, KRAS is linked to cancer.